Disc Medicine (IRON) to Release Quarterly Earnings on Thursday

Disc Medicine (NASDAQ:IRON) is expected to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($1.71) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

Disc Medicine Stock Up 3.4%

Disc Medicine stock opened at $66.20 on Wednesday. Disc Medicine has a 1-year low of $30.82 and a 1-year high of $99.50. The firm has a market capitalization of $2.50 billion, a price-to-earnings ratio of -12.37 and a beta of 0.88. The company has a current ratio of 23.45, a quick ratio of 23.45 and a debt-to-equity ratio of 0.05. The firm’s fifty day moving average price is $75.56 and its two-hundred day moving average price is $75.46.

Insider Buying and Selling at Disc Medicine

In other news, insider William Jacob Savage sold 13,093 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $91.22, for a total transaction of $1,194,343.46. Following the completion of the sale, the insider owned 75,702 shares of the company’s stock, valued at approximately $6,905,536.44. This represents a 14.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Rahul Khara sold 6,500 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $78.69, for a total transaction of $511,485.00. Following the transaction, the insider directly owned 37,793 shares of the company’s stock, valued at approximately $2,973,931.17. This trade represents a 14.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 284,761 shares of company stock worth $24,913,484 over the last quarter. Company insiders own 3.64% of the company’s stock.

Institutional Trading of Disc Medicine

A number of hedge funds have recently made changes to their positions in IRON. Persistent Asset Partners Ltd bought a new position in shares of Disc Medicine in the fourth quarter worth approximately $141,000. Russell Investments Group Ltd. increased its position in shares of Disc Medicine by 15,137.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company’s stock valued at $161,000 after purchasing an additional 2,422 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Disc Medicine by 383.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,975 shares of the company’s stock worth $211,000 after acquiring an additional 3,152 shares during the last quarter. Virtus Investment Advisers LLC grew its holdings in Disc Medicine by 34.2% during the fourth quarter. Virtus Investment Advisers LLC now owns 2,897 shares of the company’s stock valued at $230,000 after purchasing an additional 739 shares during the period. Finally, AlphaCentric Advisors LLC bought a new position in shares of Disc Medicine during the 4th quarter valued at approximately $298,000. 83.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

IRON has been the topic of a number of recent research reports. Truist Financial raised their target price on Disc Medicine from $86.00 to $114.00 and gave the company a “buy” rating in a report on Monday, November 10th. UBS Group reaffirmed an “overweight” rating on shares of Disc Medicine in a report on Thursday, January 15th. Wells Fargo & Company reduced their target price on shares of Disc Medicine from $109.00 to $78.00 and set an “overweight” rating for the company in a research note on Tuesday, February 17th. TD Cowen reiterated a “buy” rating on shares of Disc Medicine in a research note on Friday, December 19th. Finally, Stifel Nicolaus decreased their target price on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Disc Medicine has an average rating of “Moderate Buy” and an average target price of $104.82.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.